Skip to content ⤶

ICI Cardiovascular Complications Guidance

Cardiovascular complications of immuno-oncology treatments, including myocarditis, are associated with a high mortality rate. We recognise that the diverse presentations of these toxicities pose significant challenges in diagnosis and management.

Please find below a list of resources for healthcare professionals on the risk stratification, diagnosis and management of cardiovascular complications of immune-oncology treatments:

Baseline cardiac assessment:
- Baseline cardiac assessment in individuals receiving immune checkpoint inhibitors: A Joint Consensus Statement (BCOS and IOCN) - A guide for oncologists and cardiologists to navigate the delivery and implementation of baseline testing
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Management of ICI cardiovascular complications:

Investigation and management
- The Clatterbridge Cancer Centre Myocarditis Guideline
- The Clatterbridge Cancer Centre guideline on subsequent management of myocarditis
- ESMO Management of toxicities from Immunotherapy
ECG features and monitoring in suspected myocarditis
- Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis
- Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
Additional educational resources:
- British Cardio-Oncology Society (BCOS) educational resources